In this episode, Arjun Balar, MD discusses the management of adverse events in patients with advanced urothelial cancer being treated by novel therapies and is joined by Rana McKay, MD and moderator Terran Sims, MSN to review patient cases and provide answer pressing questions from the audience. Claim your credit at pce.is/GIGU.
In this second of two podcasts, discuss the management of advanced urothelial cancer with novel therapies and how to address adverse events, and concludes the episode with a review of audience questions and patient cases. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Arjun Balar, MD
Rana R. McKay, MD
Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.
Ms Sims: consulting fees: Coloplast.